MX9601368A - Metodo de tratamiento de la reestenosis por terapia genica. - Google Patents
Metodo de tratamiento de la reestenosis por terapia genica.Info
- Publication number
- MX9601368A MX9601368A MX9601368A MX9601368A MX9601368A MX 9601368 A MX9601368 A MX 9601368A MX 9601368 A MX9601368 A MX 9601368A MX 9601368 A MX9601368 A MX 9601368A MX 9601368 A MX9601368 A MX 9601368A
- Authority
- MX
- Mexico
- Prior art keywords
- restenosis
- gene therapy
- adenoviral vector
- gene
- delivering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01021—Thymidine kinase (2.7.1.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04001—Cytosine deaminase (3.5.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invencion se refiere a un método para el tratamiento de la reestenosis por terapia génica, que comprende la administracion de un adenovirus recombinante que incluye un gen suicida.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9410083A FR2723697B1 (fr) | 1994-08-17 | 1994-08-17 | Methode de traitement de la restenose par la therapie genique |
PCT/FR1995/001074 WO1996005321A1 (fr) | 1994-08-17 | 1995-08-10 | Therapie genique de la restenose au moyen de vecteur adenovial |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9601368A true MX9601368A (es) | 1998-06-30 |
Family
ID=9466347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9601368A MX9601368A (es) | 1994-08-17 | 1995-08-10 | Metodo de tratamiento de la reestenosis por terapia genica. |
Country Status (12)
Country | Link |
---|---|
US (2) | US6410011B1 (es) |
EP (1) | EP0734448A1 (es) |
JP (1) | JPH09504558A (es) |
AU (1) | AU3169495A (es) |
CA (1) | CA2174232A1 (es) |
FI (1) | FI961666A (es) |
FR (1) | FR2723697B1 (es) |
IL (1) | IL114982A (es) |
MX (1) | MX9601368A (es) |
NO (1) | NO317720B1 (es) |
WO (1) | WO1996005321A1 (es) |
ZA (1) | ZA956849B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2723697B1 (fr) * | 1994-08-17 | 1996-09-20 | Rhone Poulenc Rorer Sa | Methode de traitement de la restenose par la therapie genique |
DK0885002T3 (da) * | 1996-03-04 | 2011-08-22 | Penn State Res Found | Materialer og fremgangsmåder til forøgelse af cellulær internalisering |
DE19620308A1 (de) * | 1996-05-10 | 1997-11-13 | Franz Wolfgang M Dr | Vektor-System zur spezifischen in vivo Genexpression in glatten Gefäßmuskelzellen |
US7232899B2 (en) * | 1996-09-25 | 2007-06-19 | The Scripps Research Institute | Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use |
US6183752B1 (en) | 1997-02-05 | 2001-02-06 | Pasteur Merieux Serums Et Vaccins | Restenosis/atherosclerosis diagnosis, prophylaxis and therapy |
US6398757B1 (en) | 1997-02-07 | 2002-06-04 | Leuven Research & Development Vzw | Gene therapeutic treatment of blood vessel associated disorders |
US6087164A (en) * | 1997-10-03 | 2000-07-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for inducing tumor-specific cytotoxicity |
US7041654B2 (en) | 1997-10-03 | 2006-05-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for inducing tumor-specific cytotoxicity |
ATE344322T1 (de) | 1998-02-13 | 2006-11-15 | Koester Hubert | Verwendung von ribozymen zur bestimmung der funktion von genen |
AU759016B2 (en) | 1998-10-05 | 2003-04-03 | Penn State Research Foundation, The | Compositions and methods for enhancing receptor-mediated cellular internalization |
AU776067B2 (en) * | 1999-03-04 | 2004-08-26 | Crucell Holland B.V. | Means and methods for fibroblast-like or macrophage-like cell transduction |
WO2001055362A2 (en) * | 2000-01-31 | 2001-08-02 | The Governement Of The United States Of America, As Represented By The Secretary, Departement Of Health & Human Services, The National Institutes Of Health | Hybrid adeno-retroviral vector for the transfection of cells |
US20020164333A1 (en) * | 2000-07-10 | 2002-11-07 | The Scripps Research Institute | Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
WO2002061104A2 (en) | 2001-01-30 | 2002-08-08 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Hybrid adenoviral vector |
WO2002080977A1 (en) * | 2001-04-04 | 2002-10-17 | Delsitech Oy | Biodegradable carrier and method for preparation thereof |
WO2003083105A1 (fr) * | 2002-03-28 | 2003-10-09 | Medicalseed Co., Ltd. | Traitement et prevention de l'angiostenose |
US20040052161A1 (en) * | 2002-09-17 | 2004-03-18 | Steven Liao | Mechanical clock having wireless manipulation and adjustment function |
WO2011032100A1 (en) | 2009-09-11 | 2011-03-17 | Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of kshv vil6 and human il6 |
US11883470B2 (en) | 2016-07-25 | 2024-01-30 | The Trustees Of The University Of Pennsylvania | Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
WO1993008845A1 (en) * | 1991-11-08 | 1993-05-13 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
EP1321526A3 (en) * | 1992-11-18 | 2003-07-02 | Arch Development Corporation | Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle |
WO1994027612A1 (en) * | 1993-05-20 | 1994-12-08 | Baylor College Of Medicine | Genetic therapy for cardiovascular disease |
CN1115414C (zh) * | 1993-07-13 | 2003-07-23 | 罗纳-布朗克罗莱尔股份有限公司 | 用于基因治疗的病毒载体 |
US6682728B1 (en) * | 1993-10-13 | 2004-01-27 | The United States Of America As Represented By The Department Of Health And Human Services | Efficient and selective adenoviral-mediated gene transfer into vascular neointima |
EP0804249A2 (en) * | 1994-03-15 | 1997-11-05 | Brown University Research Foundation | Polymeric gene delivery system |
US6780406B1 (en) * | 1994-03-21 | 2004-08-24 | The Regents Of The University Of Michigan | Inhibition of vascular smooth muscle cell proliferation administering a thymidine kinase gene |
FR2723697B1 (fr) * | 1994-08-17 | 1996-09-20 | Rhone Poulenc Rorer Sa | Methode de traitement de la restenose par la therapie genique |
AUPN477695A0 (en) * | 1995-08-14 | 1995-09-07 | Commonwealth Scientific And Industrial Research Organisation | Gene therapy |
-
1994
- 1994-08-17 FR FR9410083A patent/FR2723697B1/fr not_active Expired - Fee Related
-
1995
- 1995-08-10 CA CA002174232A patent/CA2174232A1/fr not_active Abandoned
- 1995-08-10 JP JP8507070A patent/JPH09504558A/ja not_active Ceased
- 1995-08-10 US US08/633,769 patent/US6410011B1/en not_active Expired - Fee Related
- 1995-08-10 AU AU31694/95A patent/AU3169495A/en not_active Abandoned
- 1995-08-10 WO PCT/FR1995/001074 patent/WO1996005321A1/fr not_active Application Discontinuation
- 1995-08-10 EP EP95927778A patent/EP0734448A1/fr not_active Withdrawn
- 1995-08-10 MX MX9601368A patent/MX9601368A/es unknown
- 1995-08-16 ZA ZA956849A patent/ZA956849B/xx unknown
- 1995-08-17 IL IL114982A patent/IL114982A/en not_active IP Right Cessation
-
1996
- 1996-04-16 NO NO19961504A patent/NO317720B1/no unknown
- 1996-04-16 FI FI961666A patent/FI961666A/fi not_active Application Discontinuation
-
2002
- 2002-02-21 US US10/078,677 patent/US20020094324A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU3169495A (en) | 1996-03-07 |
IL114982A (en) | 2006-10-31 |
FR2723697B1 (fr) | 1996-09-20 |
CA2174232A1 (fr) | 1996-02-22 |
EP0734448A1 (fr) | 1996-10-02 |
IL114982A0 (en) | 1995-12-08 |
ZA956849B (en) | 1996-04-15 |
FR2723697A1 (fr) | 1996-02-23 |
NO961504L (no) | 1996-04-16 |
NO961504D0 (no) | 1996-04-16 |
FI961666A (fi) | 1996-06-06 |
US6410011B1 (en) | 2002-06-25 |
WO1996005321A1 (fr) | 1996-02-22 |
NO317720B1 (no) | 2004-12-02 |
FI961666A0 (fi) | 1996-04-16 |
JPH09504558A (ja) | 1997-05-06 |
US20020094324A1 (en) | 2002-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9601368A (es) | Metodo de tratamiento de la reestenosis por terapia genica. | |
CA2213343A1 (en) | Chimeric adenoviral fiber protein and methods of using same | |
ZA963434B (en) | Gene therapy using replication competent targeted adenoviral vectors. | |
EP0791050A4 (en) | VECTORS FOR TISSUE-SPECIFIC REPLICATION | |
HUT73464A (en) | Defective recombinant adenoviruses for gene therapy of tumours | |
EP0633943A4 (en) | GENTHERAPY USING TARGETED VIRAL VECTORS. | |
NZ333588A (en) | Sulphamates as anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS) | |
AU1378499A (en) | Methods for treating prostate tumors using radioactive compositions | |
GR3032744T3 (en) | Surface expression of enzyme in gene directed prodrug therapy | |
AU2552795A (en) | Safe vectors for gene therapy | |
MY117138A (en) | Coating of mineral moldings with radiation-curable preparations | |
HUT72558A (en) | Defective adenovirus vectors and use thereof in gene therapy | |
EP0688358A4 (en) | IMPROVED VECTORS FOR GENTHERAPY | |
MX9705937A (es) | Procedimiento de preparacion de genoma de adenovirus recombinantes. | |
MY114140A (en) | Novel enzymes and prodrugs for use in antibody-directed enzyme prodrug therapy. | |
EP0900849A4 (en) | GENE TRANSFER SYSTEM THROUGH RECEPTORS FOR TARGETED GENE THERAPY OF TUMORS | |
CA2234263A1 (fr) | Composition pharmaceutique contre les tumeurs et infections a papillomavirus | |
PL349489A1 (en) | Adenovirus-mediated gene therapy | |
IL131014A0 (en) | Methods for cultivating cells and propagating viruses | |
HUP9902150A3 (en) | Recombinant adenoviral vectors for human tumour gene therapy | |
ZA958128B (en) | Viral vectors and use in gene therapy | |
GB2322131B (en) | Improved retroviral vectors for gene therapy | |
EP0776972A4 (en) | GENE ENCODING THE IgG-Fc-BINDING PROTEIN | |
MX9700298A (es) | Adenovirus que comprende un gen que codifica para una no sintasa. | |
AU7538898A (en) | Processor controller for accelerating instruction issuing rate |